ArticleBiomacromolecules2026
Macrophage Membrane-Engineered Biomimetic Nanoplatform Enables Immune Evasion and Immunomodulation for Enhanced Chemo-Photodynamic Therapy.
Article in Biomacromolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes with insufficient therapeutic opportunities and poor clinical outcomes. This challenge can be addressed to a great extent by immunotherapy, but its clinical efficacy is substantially limited by the immunosuppressive tumor microenvironment. To overcome these barriers, an intelligent M1-type macrophage membrane camouflaged biomimetic nanoplatform based on cholesterol-functionalized glycopolymers bearing a photodynamic therapy (PDT)-active unit protoporphyrin IX (PpIX) and pH-responsive linkages for doxorubicin (Dox) conjugation has been developed to suppress TNBC through the combination of chemo-photodynamic therapy and immune remodeling. The therapeutic efficacy of the NP-Dox@M1 nanoplatform against metastatic TNBC was systematically evaluated in vitro through a comparative analysis of membrane-coated (NP@M1) versus uncoated (NP) constructs and drug-loaded (NP-Dox) versus drug-free formulations under conditions with or without light irradiation. The NP-Dox@M1 nanoplatform enables the synergistic combination of enhanced chemo-photodynamic therapy and immune regulation by promoting the polarization of macrophages toward an M1-like phenotype and reducing macrophage uptake, demonstrating potential immune evasion for the effective treatment of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.